Dr. Reddy’s Laboratories has announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the US, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines.

The company has collaborated with MSN Laboratories.

Dr. Reddy’s holds the exclusive marketing rights for the product in the US. MSN is responsible for the development and manufacturing of the product.

Bosutinib Tablets (400mg) was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S.

Milan Kalawadia, CEO-North America, Dr. Reddy’s Laboratories, said, “This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable.”

The Bosulif brand (400mg) had US sales of approximately USD 253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data.

Bharat Reddy, Executive Director, MSN Laboratories, added, “The successful development and commercialisation of Bosutinib Tablets demonstrates MSN’s strong scientific, regulatory, and manufacturing capabilities in complex oncology products. We remain committed to delivering high-quality, affordable medicines globally through efficient development and reliable manufacturing excellence.”

Bosulif is a registered trademark of Wyeth LLC.